Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E17.32 EPS (ttm)5.65 Insider Own0.10% Shs Outstand1.48B Perf Week-1.16%
Market Cap174.44B Forward P/E8.33 EPS next Y11.75 Insider Trans-4.76% Shs Float1.47B Perf Month6.07%
Income8.39B PEG1.69 EPS next Q2.13 Inst Own63.60% Short Float1.34% Perf Quarter21.87%
Sales34.06B P/S5.12 EPS this Y42.30% Inst Trans1.10% Short Ratio1.96 Perf Half Y9.88%
Book/sh-5.01 P/B- EPS next Y14.48% ROA11.30% Target Price104.44 Perf Year39.24%
Cash/sh- P/C- EPS next 5Y10.28% ROE-103.70% 52W Range62.55 - 100.69 Perf YTD10.53%
Dividend4.72 P/FCF24.88 EPS past 5Y36.80% ROI21.20% 52W High-2.81% Beta0.82
Dividend %4.82% Quick Ratio3.00 Sales past 5Y10.80% Gross Margin77.10% 52W Low56.45% ATR2.44
Employees30000 Current Ratio3.10 Sales Q/Q10.10% Oper. Margin39.90% RSI (14)57.27 Volatility2.41% 2.44%
OptionableYes Debt/Eq- EPS Q/Q22.50% Profit Margin24.60% Rel Volume0.80 Prev Close96.83
ShortableYes LT Debt/Eq- EarningsJul 31 BMO Payout77.50% Avg Volume10.10M Price97.86
Recom1.90 SMA200.98% SMA505.60% SMA20014.27% Volume8,507,428 Change1.06%
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jul-13-20 06:33PM  
11:45AM  
09:00AM  
Jul-10-20 01:07PM  
09:31AM  
07:25AM  
Jul-09-20 06:32PM  
Jul-08-20 11:30AM  
08:11AM  
07:27AM  
Jul-07-20 03:42PM  
11:40AM  
10:13AM  
08:53AM  
08:00AM  
06:41AM  
06:33AM  
Jul-06-20 09:59AM  
Jul-05-20 07:04AM  
Jul-03-20 09:15AM  
08:07AM  
07:00AM  
Jul-02-20 05:35PM  
12:32PM  
08:37AM  
Jul-01-20 02:08PM  
12:00PM  
09:33AM  
09:29AM  
Jun-30-20 02:35PM  
12:12PM  
09:52AM  
Jun-29-20 08:05AM  
Jun-26-20 11:45AM  
08:28AM  
08:25AM  
08:21AM  
01:15AM  
Jun-25-20 12:17PM  
09:00AM  
03:41AM  
Jun-24-20 01:43PM  
11:05AM  
09:12AM  
Jun-23-20 12:20PM  
11:33AM  
07:30AM  
Jun-22-20 12:18PM  
11:30AM  
11:30AM  
08:00AM  
Jun-19-20 07:00PM  
12:23PM  
12:08PM  
11:58AM  
11:50AM  
11:27AM  
07:41AM  
07:25AM  
Jun-18-20 10:31AM  
08:45AM  
08:00AM  
Jun-17-20 10:32AM  
07:00AM  
06:07AM  
Jun-16-20 10:31AM  
Jun-15-20 10:46AM  
09:24AM  
08:15AM  
08:00AM  
Jun-14-20 11:16AM  
07:17AM  
Jun-13-20 06:46AM  
02:30AM  
Jun-12-20 04:45PM  
03:02PM  
10:40AM  
10:23AM  
09:48AM  
09:21AM  
08:53AM  
Jun-11-20 10:56AM  
10:31AM  
09:15AM  
08:12AM  
07:01AM  
Jun-10-20 05:10PM  
04:02PM  
11:45AM  
11:30AM  
11:26AM  
10:29AM  
10:18AM  
09:50AM  
08:15AM  
07:38AM  
07:30AM  
07:26AM  
06:12AM  
06:00AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerSep 27Sale75.0215,5151,163,8730Oct 01 05:52 PM
Schumacher Laura JVice ChairmanSep 16Buy70.4225,0001,760,523164,838Sep 18 04:25 PM
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM